250 related articles for article (PubMed ID: 27401248)
1. Dysregulation of EGFR Pathway in EphA2 Cell Subpopulation Significantly Associates with Poor Prognosis in Colorectal Cancer.
De Robertis M; Loiacono L; Fusilli C; Poeta ML; Mazza T; Sanchez M; Marchionni L; Signori E; Lamorte G; Vescovi AL; Garcia-Foncillas J; Fazio VM
Clin Cancer Res; 2017 Jan; 23(1):159-170. PubMed ID: 27401248
[TBL] [Abstract][Full Text] [Related]
2. EphA2 Expression Is a Key Driver of Migration and Invasion and a Poor Prognostic Marker in Colorectal Cancer.
Dunne PD; Dasgupta S; Blayney JK; McArt DG; Redmond KL; Weir JA; Bradley CA; Sasazuki T; Shirasawa S; Wang T; Srivastava S; Ong CW; Arthur K; Salto-Tellez M; Wilson RH; Johnston PG; Van Schaeybroeck S
Clin Cancer Res; 2016 Jan; 22(1):230-242. PubMed ID: 26283684
[TBL] [Abstract][Full Text] [Related]
3. The prognostic role of ephrin A2 and endothelial growth factor receptor pathway mediators in patients with advanced colorectal cancer treated with cetuximab.
Strimpakos A; Pentheroudakis G; Kotoula V; De Roock W; Kouvatseas G; Papakostas P; Makatsoris T; Papamichael D; Andreadou A; Sgouros J; Zizi-Sermpetzoglou A; Kominea A; Televantou D; Razis E; Galani E; Pectasides D; Tejpar S; Syrigos K; Fountzilas G
Clin Colorectal Cancer; 2013 Dec; 12(4):267-274.e2. PubMed ID: 24050852
[TBL] [Abstract][Full Text] [Related]
4. EphB2 stem-related and EphA2 progression-related miRNA-based networks in progressive stages of CRC evolution: clinical significance and potential miRNA drivers.
De Robertis M; Mazza T; Fusilli C; Loiacono L; Poeta ML; Sanchez M; Massi E; Lamorte G; Diodoro MG; Pescarmona E; Signori E; Pesole G; Vescovi AL; Garcia-Foncillas J; Fazio VM
Mol Cancer; 2018 Nov; 17(1):169. PubMed ID: 30501625
[TBL] [Abstract][Full Text] [Related]
5. EPHA2 Is a Predictive Biomarker of Resistance and a Potential Therapeutic Target for Improving Antiepidermal Growth Factor Receptor Therapy in Colorectal Cancer.
Martini G; Cardone C; Vitiello PP; Belli V; Napolitano S; Troiani T; Ciardiello D; Della Corte CM; Morgillo F; Matrone N; Sforza V; Papaccio G; Desiderio V; Paul MC; Moreno-Viedma V; Normanno N; Rachiglio AM; Tirino V; Maiello E; Latiano TP; Rizzi D; Signoriello G; Sibilia M; Ciardiello F; Martinelli E
Mol Cancer Ther; 2019 Apr; 18(4):845-855. PubMed ID: 30824612
[TBL] [Abstract][Full Text] [Related]
6. EphA2 receptor activation with ephrin-A1 ligand restores cetuximab efficacy in NRAS-mutant colorectal cancer cells.
Cuyàs E; Queralt B; Martin-Castillo B; Bosch-Barrera J; Menendez JA
Oncol Rep; 2017 Jul; 38(1):263-270. PubMed ID: 28560458
[TBL] [Abstract][Full Text] [Related]
7. Forkhead box K2 promotes human colorectal cancer metastasis by upregulating ZEB1 and EGFR.
Du F; Qiao C; Li X; Chen Z; Liu H; Wu S; Hu S; Qiu Z; Qian M; Tian D; Wu K; Fan D; Nie Y; Xia L
Theranostics; 2019; 9(13):3879-3902. PubMed ID: 31281520
[No Abstract] [Full Text] [Related]
8. RasGRP1 is a potential biomarker to stratify anti-EGFR therapy response in colorectal cancer.
Gbenedio OM; Bonnans C; Grun D; Wang CY; Hatch AJ; Mahoney MR; Barras D; Matli M; Miao Y; Garcia KC; Tejpar S; Delorenzi M; Venook AP; Nixon AB; Warren RS; Roose JP; Depeille P
JCI Insight; 2019 Jun; 5(15):. PubMed ID: 31237864
[TBL] [Abstract][Full Text] [Related]
9. MicroRNA-425-5p Expression Affects BRAF/RAS/MAPK Pathways In Colorectal Cancers.
Angius A; Pira G; Scanu AM; Uva P; Sotgiu G; Saderi L; Manca A; Serra C; Uleri E; Piu C; Caocci M; Ibba G; Zinellu A; Cesaraccio MR; Sanges F; Muroni MR; Dolei A; Cossu-Rocca P; De Miglio MR
Int J Med Sci; 2019; 16(11):1480-1491. PubMed ID: 31673240
[TBL] [Abstract][Full Text] [Related]
10. miR-145-5p restrained cell growth, invasion, migration and tumorigenesis via modulating RHBDD1 in colorectal cancer via the EGFR-associated signaling pathway.
Niu Y; Zhang J; Tong Y; Li J; Liu B
Int J Biochem Cell Biol; 2019 Dec; 117():105641. PubMed ID: 31693935
[TBL] [Abstract][Full Text] [Related]
11. Predictive and prognostic implications of 4E-BP1, Beclin-1, and LC3 for cetuximab treatment combined with chemotherapy in advanced colorectal cancer with wild-type KRAS: Analysis from real-world data.
Guo GF; Wang YX; Zhang YJ; Chen XX; Lu JB; Wang HH; Jiang C; Qiu HQ; Xia LP
World J Gastroenterol; 2019 Apr; 25(15):1840-1853. PubMed ID: 31057298
[TBL] [Abstract][Full Text] [Related]
12. Expression of the receptor tyrosine kinase EphA2 is increased in smokers and predicts poor survival in non-small cell lung cancer.
Brannan JM; Dong W; Prudkin L; Behrens C; Lotan R; Bekele BN; Wistuba I; Johnson FM
Clin Cancer Res; 2009 Jul; 15(13):4423-30. PubMed ID: 19531623
[TBL] [Abstract][Full Text] [Related]
13. miR-181a is associated with poor clinical outcome in patients with colorectal cancer treated with EGFR inhibitor.
Pichler M; Winter E; Ress AL; Bauernhofer T; Gerger A; Kiesslich T; Lax S; Samonigg H; Hoefler G
J Clin Pathol; 2014 Mar; 67(3):198-203. PubMed ID: 24098024
[TBL] [Abstract][Full Text] [Related]
14. Receptor tyrosine kinase-dependent PI3K activation is an escape mechanism to vertical suppression of the EGFR/RAS/MAPK pathway in KRAS-mutated human colorectal cancer cell lines.
Vitiello PP; Cardone C; Martini G; Ciardiello D; Belli V; Matrone N; Barra G; Napolitano S; Della Corte C; Turano M; Furia M; Troiani T; Morgillo F; De Vita F; Ciardiello F; Martinelli E
J Exp Clin Cancer Res; 2019 Jan; 38(1):41. PubMed ID: 30691487
[TBL] [Abstract][Full Text] [Related]
15. Cetuximab enhances the anti-tumor function of macrophages in an IL-6 dependent manner.
Zhao Y; Liu X; Huo M; Wang Y; Li Y; Xu N; Zhu H
Life Sci; 2021 Feb; 267():118953. PubMed ID: 33359746
[TBL] [Abstract][Full Text] [Related]
16. Interactions between EGFR and EphA2 promote tumorigenesis through the action of Ephexin1.
Kim J; Chang IY; You HJ
Cell Death Dis; 2022 Jun; 13(6):528. PubMed ID: 35668076
[TBL] [Abstract][Full Text] [Related]
17. PEAK1, acting as a tumor promoter in colorectal cancer, is regulated by the EGFR/KRas signaling axis and miR-181d.
Huang L; Wen C; Yang X; Lou Q; Wang X; Che J; Chen J; Yang Z; Wu X; Huang M; Lan P; Wang L; Iwamoto A; Wang J; Liu H
Cell Death Dis; 2018 Feb; 9(3):271. PubMed ID: 29449544
[TBL] [Abstract][Full Text] [Related]
18. EphA2/Ephrin-A1 Mediate Corneal Epithelial Cell Compartmentalization via ADAM10 Regulation of EGFR Signaling.
Kaplan N; Ventrella R; Peng H; Pal-Ghosh S; Arvanitis C; Rappoport JZ; Mitchell BJ; Stepp MA; Lavker RM; Getsios S
Invest Ophthalmol Vis Sci; 2018 Jan; 59(1):393-406. PubMed ID: 29351356
[TBL] [Abstract][Full Text] [Related]
19. MicroRNA-7 expression in colorectal cancer is associated with poor prognosis and regulates cetuximab sensitivity via EGFR regulation.
Suto T; Yokobori T; Yajima R; Morita H; Fujii T; Yamaguchi S; Altan B; Tsutsumi S; Asao T; Kuwano H
Carcinogenesis; 2015 Mar; 36(3):338-45. PubMed ID: 25503932
[TBL] [Abstract][Full Text] [Related]
20. S897 phosphorylation of EphA2 is indispensable for EphA2-dependent nasopharyngeal carcinoma cell invasion, metastasis and stem properties.
Li JY; Xiao T; Yi HM; Yi H; Feng J; Zhu JF; Huang W; Lu SS; Zhou YH; Li XH; Xiao ZQ
Cancer Lett; 2019 Mar; 444():162-174. PubMed ID: 30583071
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]